News

The post hoc analysis published in JAMA Dermatology studied the safety and efficacy of tralokinumab in adults aged 65 and older.

The American Acne and Rosacea Society selected Bunick’s research on tetracycline-class compounds for the award.

The treated areas remained clear up to 18 months after treatment with follicular unit excision.

Investigators recommended further studies exploring the confounding variables that may contribute to higher rates of skin cancers in this patient population.

There are simple tools that can help us achieve the best employment contract.

Click here to answer this week's melasma poll.

Patients with psoriasis treated with IL-23i and IL-17i had a decreased risk of developing pneumonia, otitis media, and upper respiratory tract infections.

Scientists say the new findings could lead to new drugs for vitiligo and other pigmentation diseases.

Longevity Playbook helps individuals understand how their lifestyle choices affect signs of aging.

This Hair Loss Awareness Month, let us know your experiences. Click here to answer this week's poll.

All participants showed fewer fine lines by the end of the 12-week study.

Keep up with the latest headlines in dermatology from the past week, including growing concerns of a dermatologist shortage in Ontario, LEO Pharma's acquisition of Timber Pharmaceuticals, and more. This week, we have also included a patient-forward rundown of top headlines to share with your patients.

ICYMI, this week we had stories about clascoterone cream 1% for acne vulgaris management, CRH-R1 increases in psoriasis and actinic keratosis mast cells, cannabinoid use in dermatology, and more.

Lauren Miller, MPAS, and T.J. Chao, MPAS, emphasized that clinicians need to be an advocate for patients and take that extra step to educate.

Attendees learned about a variety of professions in healthcare and how to prepare for them.

Providers have been eagerly awaiting the approval of VP-102, as molluscum contagiosum accounts for approximately 1% of all diagnosed skin conditions.

The OCCUPES study examined the patient burden associated with foot dermatoses and work-related skin diseases and the implications of a prevention program.

Researchers noted a lack of significant differences in access to biologics among different populations.

The Sanofi-Regeneron Diversity, Equity, and Inclusion Mid-Career Award applications will open September 15.

As few as 90% of study participants without visible actinic keratosis lesions displayed inflammatory reactions indicative of the presence of subclinical AK lesions.

Alexandra Golant, MD, and Mona Shahriari, MD, shared pearls regarding the role of nonsteroidal topicals in the treatment of plaque psoriasis.

The dietary supplement industry seeks to help consumers age gracefully.

This week’s collection of the latest dermatologic studies covers PPT5α for androgenetic alopecia, fractional ablative CO2 laser and concurrent isotretinoin treatment for acne scars, vitamin D insufficiency and 25-hydroxy vitamin D levels related to cutaneous melanoma, and a literature review of baricitinib for alopecia areata.

Among children and adolescents with atopic dermatitis, higher severity led to more school absences.

The topical cream is the first epidermolysis bullosa treatment to receive Breakthrough Therapy designation from the FDA.

The novel therapeutic approach may be promising for patients with the mast cell-dependent disease, which has limited treatment options despite the substantial burden associated with the condition.

Risk of recurrence or death was reduced by 58% compared to placebo.

Cannabis-based personal care products suddenly seem ubiquitous all over the market, where CBD is a featured ingredient in everything from moisturizers and lotions to makeup.

Verrica’s statement follows the FDA’s warning from June 1, 2023.

In this week’s Pointers With Portela, the 208SkinDoc asks consumers skin care trivia questions about vitamin C, layers of the skin, keratosis pilaris, and more.